James Roberts, MD
Cardiovascular Disease · Monroe, NCNPI 1083657522
Payments from drug & device makers
Across 281 payments — averaging $97.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$20K
- Novartis$976
- Boehringer Ingelheim$751
- Johnson & Johnson$698
- Boston Scientific$605
- AstraZeneca$492
- plus $3K from 24 others
What the payments were for
- Food & beverage$8,55099%
- Education$501%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 53 | $20,392 |
| Novartis | 35 | $976 |
| Boehringer Ingelheim | 18 | $751 |
| Johnson & Johnson | 31 | $698 |
| Boston Scientific | 18 | $605 |
| AstraZeneca | 24 | $492 |
| Heartflow, Inc. | 11 | $422 |
| Pfizer | 10 | $309 |
| Abbott | 5 | $282 |
| E.r. Squibb & Sons, L.L.C. | 14 | $272 |
| Edwards Lifesciences | 2 | $254 |
| Bayer | 12 | $240 |
| Janssen Scientific Affairs, LLC | 3 | $194 |
| Amarin Pharma, Inc. | 2 | $183 |
| Daiichi Sankyo Inc. | 1 | $130 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $129 |
| Esperion Therapeutics, Inc. | 5 | $117 |
| Sanofi-aventis U.S. LLC | 2 | $115 |
| Scpharmaceuticals Inc. | 5 | $105 |
| Akcea Therapeutics, Inc. | 1 | $103 |
| Kiniksa Pharmaceuticals, Ltd. | 4 | $92 |
| Novo Nordisk | 4 | $86 |
| Medtronic | 1 | $84 |
| Irhythm Technologies, Inc. | 2 | $84 |
| Cvrx, Inc. | 2 | $62 |
| Regeneron Healthcare Solutions, Inc. | 3 | $51 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $47 |
| Kestra Medical Technology Services, Inc. | 2 | $40 |
| Mannkind Corporation | 1 | $34 |
| Livanova USA, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$436
- JARDIANCE$356
- Edwards SAPIEN 3 Transcatheter Heart Valve$254
- XARELTO$232
- WATCHMAN FLX$157
- INJECTAFER$130
- Watchman$121
- ENTRESTO$120
- LEQVIO$117
- CardioMEMS HF System$114
- DISEASE STATE$108
- CARDIOMEMS$108
- TEGSEDI$103
- ELIQUIS$102
- WAINUA$101
How this compares
$27,372 in reported general payments places this provider in the 80th percentile of 727 cardiovascular disease providers in North Carolina.
See all cardiovascular disease providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 389 | $389,318 |
| Repatha SureclickEvolocumab | 404 | $332,585 |
| EntrestoSacubitril/Valsartan | 115 | $135,826 |
| XareltoRivaroxaban | 77 | $89,878 |
| Praluent PenAlirocumab | 29 | $35,154 |
| FarxigaDapagliflozin Propanediol | 24 | $23,051 |
| OzempicSemaglutide | 21 | $21,252 |
| JardianceEmpagliflozin | 18 | $18,891 |
| BrilintaTicagrelor | 32 | $15,559 |
| Repatha PushtronexEvolocumab | 24 | $14,120 |
| Repatha SyringeEvolocumab | 16 | $13,662 |
| MounjaroTirzepatide | 11 | $12,998 |
| Rosuvastatin Calcium | 1,046 | $10,567 |
| Ranolazine ErRanolazine | 85 | $8,209 |
| Flecainide Acetate | 183 | $5,998 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $309 | $389,318389 claims |
| NovartisEntresto | $976 | $135,826115 claims |
| Johnson & JohnsonXarelto | $698 | $89,87877 claims |
| AstraZenecaFarxiga, Brilinta | $492 | $38,61056 claims |
| Novo NordiskOzempic | $86 | $21,25221 claims |
| Boehringer IngelheimJardiance | $751 | $18,89118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 727 cardiovascular disease providers in North Carolina.
Other cardiovascular disease in Monroe
- John AlexanderDurham$76.8M
- Christopher GrangerDurham$24.7M
- Jonathan PicciniDurham$14.3M
- Adrian HernandezDurham$13.2M
- Gary FelkerDurham$12.7M
- Robert MentzDurham$6M
- Michael ShapiroWinston-Salem$5.4M
- Kirkwood AdamsChapel Hill$4.9M
- Matthew JanikWilmington$4M
- Nishant ShahDurham$3.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.